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Background. Excess circulating thyroid hormones are associated with increased cardiac atrial natriuretic peptide (ANP) secretion
but the exact mechanisms involved have not been fully elucidated in vivo. Methods. To examine whether thyroid hormone
regulation of ANP secretion is the result of a direct action on the myocardium and/or of an indirect action through alterations
in the peripheral circulation, plasma ANP levels (baseline and volume expansion-induced) were evaluated in 14 healthy men,
before and after triiodothyronine (T3) administration. Results.T 3 administration was followed by a signiﬁcant increase in serum
T3 levels and a signiﬁcant decrease in serum TSH levels, without signiﬁcantly aﬀecting ANP levels. Systemic vascular resistance,
plasmarenninactivity(PRA),andaldosterone(ALDO)levels,aswell asindicesofleftatrialfunction,werenotsigniﬁcantlyaltered,
despite a signiﬁcant increase in cardiac output. Plasma volume expansion, induced by a 1500ml normal saline (NSal) infusion,
both before and after T3 administration, was followed by a signiﬁcant decrease in PRA and ALDO and a signiﬁcant increase in
plasma ANP levels, without signiﬁcantly aﬀecting the mean blood pressure (BP) and heart rate (HR) in each study period. The
NSal-induced response, measured as the integrated area under the curve corrected for baseline values (-AUC), was not diﬀerent
after T3 administration for ANP, ALDO, PRA, HR, and mean BP. Conclusion. In vivo thyroid hormone-induced myocardial ANP
secretion is the result of an indirect action mainly through hemodynamic changes that increase atrial stretch.
1.Introduction
Excess thyroid hormone is associated with changes in
cardiovascularsystem, includingincrease in heart rate, blood
volume, cardiac contractility, and cardiac output [1, 2]a n d
decrease in systemic vascular resistance, whereas thyroid
hormone deﬁciency has been associated with the opposite
eﬀects [3]. It has been postulated that these changes are the
result of both a direct regulation of cardiac-speciﬁc genes by
triiodothyronine (T3)[ 4, 5]a n di n d i r e c tc h a n g e si nh e m o -
dynamic function [6].
Atrial natriuretic peptide (ANP) is a hormone synthe-
sized by atrial cardiomyocytes [7, 8] and is involved in blood
pressure and electrolyte homeostasis [9]. Human studies
have shown that plasma ANP secretion is aﬀected by thyroid
hormones, being higher in hyperthyroid patients compared
to euthyroid controls [10–12]a n dr e t u r n i n gt on o r m a l
levels after appropriate treatment [13]. There is a strong2 Cardiology Research and Practice
Table 1: Clinical and laboratory characteristics of the study
population before and after T3 administration.
Parameter Before T3 After T3 P value
Heart rate, beats/min 72 ±77 5 ±6 .061
Mean blood pressure, mmHg 117 ±13 117 ±10 .966
T3,n m o l / L 1 .80 ±0.64 .3 ±1.0 <.001
T4, nmol/L 107 ±18 97 ±20 .018
TSH, µU/mL 1.04 ±0.70 0.09 ±0.04 <.001
ANP, pmol/L 10.4 ±2.91 1 .8 ±4.9 .256
PRA, nmol/L/h 1.8 ±1.23 2.2 ±0.9 .099
ALDO, pmol/L 633 ±472 665 ±325 .836
ALDO: plasma aldosterone; ANP: plasma atrial natriuretic peptide; PRA,
plasma renin activity.
positive relationship between circulating thyroid hormones
and both atrial and ventricular ANP mRNA contents
[14, 15], supporting the hypothesis that ANP synthesis
and/or secretion from atrial cardiomyocytes remain under
thyroid hormone control.
Theexactmechanism(s) bywhich thyroidhormonesreg-
ulate cardiac ANP secretion have not been fully elucidated.
In vitro studies, in rat atrial myocytes, have shown a direct,
dose-dependent stimulation of ANP synthesis and secretion
by thyroid hormones [16], but in vivo studies are missing.
On the other hand, atrial stretch and/or pressure within the
atria is considered the primary mechanism that regulates
ANP secretion from cardiomyocytes [17, 18]. Therefore, in
chronic hyperthyroidism, the increased ANP secretion could
be the result of both the direct action of thyroid hormones
on the myocardium and/or the indirect action through
the alterations in peripheral circulation that may drive the
change in cardiac work [19–21]. It is not known which of the
above mechanisms predominates in vivo.
The aim of this study was to examine whether in vivo
thyroid hormone regulation of ANP secretion is the result
of a direct action on the myocardium and/or of an indirect
action through the alterations they pose in the peripheral
circulation.
2.Materialsand Methods
2.1. Design. We examined the cardiac ANP secretion (base-
line and volume expansion induced) in healthy subjects
before and after per os T3 administration for 3 days to
establish serum T3 levels compatible with hyperthyroidism.
Fourteen healthy male volunteers were recruited in the
study (mean age 29 ± 4.3 years). None of them was using
any medication known to interfere with thyroid hormones
metabolism or cardiovascular system function. There was no
dietary restriction. 50µgT 3 was administered per os twice
daily for three days. To exclude serum T3 level variation
(due to its T1/2 of ∼8h o u r s ) ,b e f o r eT 3 initiation and in
the morning of the fourth day, the participants reported
in the testing room between 8:00AM and 8:30AM after an
overnight fasting.
A heparinized indwelling intravenous (IV) line was
placed in a forearm vein, and the subject remained in the
supine position until the end of the study. Blood samples
for measurement of ANP, PRA, ALDO, T4,T 3,T S H ,s e r u m
creatinine, sodium, and potassium levels were obtained after
30minutes of being in the supine position before (i.e.,
baseline) and after a 1500mL normal saline (NSal) infusion
(IV, rate 25mL/min). New blood samples were thereafter
obtained for ANP, PRA, and ALDO measurement at 30,
60, 75, 90, and 120 minutes from the completion of NSal-
induced volume expansion (60 minutes from initiation of
NSal). All blood samples were immediately centrifuged, and
plasma or serum was separated and frozen at −70◦Cu n t i l
assayed. For ANP determinations, venous blood was drawn
directly into ice-chilled disposable glass tubes containing
EDTA (1mg/mL) and 500IU/mL aprotinin. Plasma was
immediately separated by centrifugation for 15 minutes at
4◦C and stored frozen at −70◦C until the assay. Plasma
ANP levels were measured by RIA as previously described
[13] using an antiserum to human ANP (1–28) (Nichols
Institute Diagnostics LtD., UK). Assay results were corrected
for recovery. PRA was measured using solid-phase RIA from
DiaSorin (Saluggia, Italy). For the statistical analysis, all PRA
levels below the sensitivity value (0,2ng/mL/hr) were set at
this level. Serum ALDO, T3,T 4, and TSH concentrations
were measured using commercial RIA kits. Serum and
urine creatinine and electrolytes were measured by routine
laboratory methods.
Additionally, two urine samples were collected for two-
and- a- half-hour periods, at baseline and after NSal infusion
for urine ALDO, electrolytes, and creatinine level measure-
ment. Baseline and 60- and 120-minute blood pressure (BP)
and heart rate (HR) were recorded. Mean arterial blood
pressure (MAP) was calculated as follows:
MAP = diastolic BP +

1
3
pulse pressure

. (1)
MAP was used for the determination of thesystemic vascular
resistance (SVR) according to the formula
SVR =
MAP
cardiac output
. (2)
All participants underwent a comprehensive 2D and tissue
Doppler imaging transthoracic echocardiography at baseline
(i.e., before treatment with T3) and after 3 days of treatment,
performed by a single experienced echocardiographer with
the ultrasound apparatus ATL-Ultramark 9 (Bothell, Seattle,
USA) and a 2.5MHz transducer. Complete M mode, two
dimensional, andspectral andcolorDopplerrecordingswere
made withsubjectsintheleftlateraldecubituspositionusing
conventional parasternal and apical views, according to the
standardization of the American Society of Echocardiogra-
phy [22]. Three consecutive sinus beats were measured, and
the averaged Doppler analysis of the transmitral early (E)
and late (A) inﬂow velocity was performed in the apical 4-
chamber view. Systolic function of the left ventricle was also
evaluated. The study was conducted in accordance with the
1964 Declaration of Helsinki and was approved by the ethicsCardiology Research and Practice 3
Table 2: Echocardiographic characteristics of the study population
before and after T3 administration.
Parameter Before T3 After T3 P value
Left atrial diameter,
cm
3.38 ±0.25 3.31 ± 0.27 .660
LV end-systolic
diameter, cm
3.32 ±0.25 3.09 ± 0.26 .024
LV end-systolic
volume, mL
45.5 ±8.23 8 .2 ± 7.5 .034
Shortening fraction,
%
33.6 ±0.93 9 .6 ± 2.8 .002
Ejection fraction, % 62.1 ±1.46 9 .8 ± 3.4 .001
Mean V(cf)
shortening, circ/sec
1.14 ±0.07 1.43 ± 0.11 <.001
Stroke volume, mL 73.8 ±10.78 7 .1 ± 12.1 .010
Stroke index, mL/m2 37.6 ±6.74 6 ±5.9 .049
LV ejection time,
msec
284.7 ±20.4 268 ±14.4 .069
Cardiac output,
L/min
4.97 ±0.62 6.51 ± 0.98 .038
LV PET/ET ratio 0.27 ±0.06 0.28 ± 0.03 .749
Peak E velocity, m/sec 0.73 ±0.13 0.59 ± 0.12 .006
Peak A velocity, m/sec 0.44 ±0.04 0.48 ± 0.05 .440
Acceleration velocity,
m/sec2 7.3 ±1.65 .2 ± 1.8 .018
SVR,
mmHg·mL−1·min−1 24.5 ±2.91 8 .2 ± 2.7 .046
LV: left ventricular; PET/ET: pre-ejection/ejection time; SVR: systemic
vascular resistance; V(cf): velocity of circumference ﬁber.
Table 3: Area under the curve diﬀerences in clinical and laboratory
characteristics following normal saline-induced plasma volume
expansion before and after T3 administration in the study popu-
lation.
Parameter
Δ-AUC P value
Before T3 After T3
Heart rate, beats
per minute ∗ hour 0.28 ±19 5, 15 ± 14 .457
Mean BP, mmHg ∗
hour
−4.43 ±45 2.58 ± 28.8 .668
ANP, pmol/L ∗
hour 18.7 ±11.12 2 .7 ± 12.6 .212
PRA, nmol/L/h ∗
hour
−1.67 ±1.42 −0.72 ±1.42 .122
ALDO, pmol/L ∗
hour
−3.08 ±3.9 −3.08 ±1.36 1.000
Δ-AUC: area under the curve diﬀerences; ALDO: plasma aldosterone; ANP:
plasma atrial natriuretic peptide; PRA: plasma renin activity.
committee at the HAF and VA General Hospital of Athens.
All participants provided an informed consent.
2.2. Statistical Methods. The hormone responses were cal-
culated either as the peak minus baseline (or Δ response)
or as the integrated area under the curve (AUC) values
on the baseline (0 minute) corrected response, using the
trapezoidal model. One-way ANOVA and paired t-test were
used for statistical comparisons in each group. Nonpaired
t-test and Mann Whitney, for non-parametric data, were
used for comparisons between groups. Results are expressed
as the mean ± standard deviation (SD). Diﬀerences were
considered signiﬁcant at the level of P<. 05.
3.Results
T3 administration resulted in a signiﬁcant increase in serum
T3, a signiﬁcant decrease in serum TSH, and a small but
signiﬁcant decrease in serum T4 levels (Table 1). Mean BP
and HR were not signiﬁcantly aﬀected by T3 administration.
Similarly, the induced hyperthyroid serum T3 levels resulted
in a nonsigniﬁcant increase in plasma ANP, ALDO, and PRA
(Table 1). T3 administration was followed by a signiﬁcant
increase in shortening fraction, velocity of circumferential
ﬁber shortening, ejection fraction, stroke volume, stroke
index, and cardiac output and a signiﬁcant decrease in
left ventricular (LV) end-systolic diameter, LV end-systolic
volume, LV ejection time, peak E velocity, acceleration
velocity, and systemic vascular resistance (Table 2). On the
contrary, peak A velocity and left atrial diameter were not
signiﬁcantly aﬀected (Table 2).
The NSal-induced plasma volume expansion was fol-
lowed by a signiﬁcant decrease in PRA and ALDO levels
without signiﬁcantly aﬀecting MAP and heart rate over
each study period (i.e., before and after T3 administration;
Table 3). On the contrary, plasma ANP levels increased
signiﬁcantly compared with baseline values in both study
periods (Table 3, Figure 1). However, hormone responses to
NSal-induced volume expansion, measured as the integrated
area under the curve values corrected on the baseline (Δ
AUC), were comparable before and after T3 administration
f o rA N P ,P R A ,a n dA L DO( Table 3, Figure 1).
Plasma volume expansion did not alter urine ALDO
excretion but aﬀected the urine electrolyte excretion. Urine
sodium and potassium levels increased signiﬁcantly after
NSal-induced volume expansion compared to levels before
NSal infusion (Table 4) and to comparable degree in both
study periods that is, the NSal-induced signiﬁcant changes
(Δ responses) were comparable before and after T3 adminis-
tration.
4.Discussion
Atrial stretch is the primary factor that regulates ANP secre-
tion. This has been shown in isolated cardiac preparations
[23, 24] and in intact animals with volume expansion or
direct atrial distention [24–26]. However, in vitro studies
in rat atrial myocyte cultures have shown that ANP syn-
thesis and secretion are also stimulated directly by thyroid
hormones in a dose-dependent manner [16]. There are no
data in vivo, indicating direct or indirect thyroid hormone
stimulatory eﬀect on myocardial ANP secretion.
Our study is the ﬁrst to show that a short-term increase
in T3 levels, induced by an exogenous administration of4 Cardiology Research and Practice
Table 4: Urinary electrolyte excretion before and after normal saline-induced plasma volume expansion at baseline and after T3
administration.
Parameter Before T3 After T3
Before NS After NS Δ Response Before NS After NS Δ Response
Aldo/creatinine, pmol/gr 113 ± 45 115 ±51 55 ±192 168 ±190 124 ±96 9 ±89
Na/creatinine, mEq/gr 111 ± 84 451 ±278† 340 ±288 113 ±70 338 ±231† 224 ±186
K/creatinine, mEq/gr 29 ± 12 76 ± 21∗ 47 ±18 34 ±17 83 ±40∗ 49 ±34
Ca/creatinine, mg/gr 167 ± 56 285 ±161 119 ±190 224 ±84 248 ±152 23 ±179
P/creatinine, mg/gr 611 ± 161 456 ±222 −155 ±120 597 ±223 345 ±191 −251 ± 276
Mg/creatinine, mg/gr 49 ± 24 109 ±101 60 ±112 83 ±47 72 ±42 −11 ± 23
∗P <. 01 compared to values before plasma volume expansion.
†P <. 05 compared to values before plasma volume expansion.
NS: normal saline-induced plasma volume expansion.
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Figure 1: Mean (+SD) ANP values following administration
of normal saline. The lines represent subjects before T3 (open
circles) and after T3 administration (black circles). The mean
integrated AUC values together with SEM are shown in the
insets, with bars representing subjects before (white) and after
T3 administration (black) (ANP units pmol/L.h). There was no
diﬀerence in the integrated AUC values when responses before and
after T3 administration were compared.
T3,d e s p i t er e a c h i n gT 3 values comparable to that seen in
hyperthyroidism, did not have any signiﬁcant impact on
plasma ANP levels. We administered T3 f o r3d a y s ,a st h e7 2 -
hour length has been reported to be an adequate time frame
for a T3-induced ANP-mRNA synthesis and subsequent
signiﬁcant protein secretion. Argentin et al. [27]h a v e
demonstrated that treatment of neonatal rat cardiomyocytes
(primary cultures) with T3 results in a signiﬁcant increase in
pronatriodilantin (the precursor for ANP) mRNA, whereas
Matsubara et al. [16] have shown a signiﬁcant increase in
secreted ANP levels following treatment with T3 in primary
cultures. The eﬀect in the former study was already apparent
at 12 hours and reached its maximal eﬀect at 48 hours [27],
whilst in the later became apparent at 48 hours [16]. The
stimulatory eﬀect of T3 was near maximal at a concentration
of5×10
−9 M[27],which correlatesverywellwiththeaﬃnity
of T3 for its nuclear receptor [28].
Our study is in accordance with previous studies show-
ing a signiﬁcant increase in LV contractility following T3
administration, resulting in a profound increase in stroke
volume, cardiac output, and cardiac index [1, 2]. However,
the non-signiﬁcant inﬂuence of short-term hyperthyroidism
in left atrial diameter and in peak A velocity, which reﬂect
atrial contraction, indicate that the resulting alterations in
cardiac preloading conditions were not suﬃcient enough to
signiﬁcantly aﬀect atrial wall stretch. On the other hand, the
signiﬁcant decrease in peak E velocity, which represents an
early active relaxation of the left ventricle, in conjunction
with the unchanged peak A velocity and left atrial diameter,
may indicate a more active relaxation of the left ventricle
and rapid ﬁlling phase [29–31] without signiﬁcant change
in atrial function. Nevertheless, if the action of thyroid
hormones were to be direct on cardiac myocytes, one should
expect a signiﬁcant increase in plasma ANP levels following
T3 administration. The above-mentioned alterations in
cardiovascular system do not seem enough to increase atrial
stretch and hence ANP secretion.
In healthy men, blood volume expansion has previously
been shown to increase plasma ANP levels, and this increase
closely correlates with the relative intravascular expansion
[32]. Intravascular volume expansion following NSal infu-
sion in our subjects is validated by the signiﬁcant decrease
of PRA and ALDO levels. The comparable NSal-induced
decrease in PRA and serum ALDO levels before and after
T3 administration and the non-signiﬁcant change in the
MAP and heart rate indicate comparable plasma volume
expansions, which have been proved to induce increased
cardiac preload [33, 34], velocity of the diastolic rapid ﬁlling
phase [29, 30], cardiac output and stroke volume [34–36].
In agreement this, a comparable amount of NSal-induced
natriuresis was observed in our study participants before
and after T3 administration. Therefore, thyroid hormone
action inourpopulationwasexertedpredominantlythrough
indirect modiﬁcationoftheperipheralcardiovascularsystem
rather than a directed eﬀect.
Our observation that the short-term hyperthyroid T3
levels in normal men do not aﬀect baseline plasma ANP
levels is in contrast to what is seen in chronic hyperthyroidCardiology Research and Practice 5
patients, where ANP levels are signiﬁcantly increased [10–
13]. The possibility that this ﬁnding is attributed to diﬀerent
serum T4 levels should be excluded taking into account
that the stimulating eﬀect of T4 on cellular ANP content
and ANP-mRNA levels in rat atria is entirely induced after
its conversion to T3 by type I 5 -deiodinase [37]. Based
on our observations, we can speculate that the increased
plasma ANP levels in long-lasting hyperthyroidism are
mainly the result of hemodynamic changes on the heart and
peripheral circulation that move the cardiovascular system
to a new functional equilibrium accompanied by increased
atrial stretch. This is supported by the fact that hyperthyroid
patients with atrial ﬁbrillation have signiﬁcantly higher
plasma ANP levels compared to patients without atrial
ﬁbrillation [38]. Additionally, artiﬁcial pacing in intact
animals [39]a sw ella sinh um a n s[40]increasesthesecretion
of ANP through the elevation of atrial pressure, despite
the stable normal thyroid hormone levels. The nondiﬀerent
baseline and post NSal-infusion plasma ANP levels in our
study may indicate that short-term hyperthyroid serum T3
levelsare not able to induce hemodynamic changes suﬃcient
enough to increase atrial stretch.
In conclusion, our data indicate that thyroid hormone-
induced myocardial ANP secretion in healthy subjects is
not the result of a direct action on the myocardium,
rather, it is mainly the result of an indirect modiﬁcation in
cardiovascular hemodynamics that lead to increased atrial
stretch. More studies are needed to replicate these results and
conﬁrm this evidence.
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